Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease Findings From the INternational VErapamil-SR/Trandolapril STudy

Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Rd, PO Box 100277, Gainesville, FL 32610-0277, USA.
Hypertension (Impact Factor: 6.48). 12/2009; 55(1):48-53. DOI: 10.1161/HYPERTENSIONAHA.109.142240
Source: PubMed


Hypertension is a common risk factor for peripheral arterial disease (PAD). Guidelines suggest treating PAD patients to a blood pressure <130/80 mm Hg; therefore, our objective was to explore whether attainment of this target blood pressure is associated with improved outcomes. We performed a post hoc analysis of the INternational VErapamil-SR/Trandolapril STudy, a randomized clinical trial, which included hypertensive patients with concomitant PAD and coronary artery disease. There were 2699 PAD patients followed for a mean of 2.7 years (60 970 patient-years). The primary outcome, all-cause death, nonfatal myocardial infarction, or nonfatal stroke, occurred in 16.3% of PAD patients versus 9.2% without PAD (adjusted hazard ratio: 1.26 [95% CI: 1.13 to 1.40]; P<0.0001). The primary outcome occurred least frequently among PAD patients treated to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg. PAD patients displayed a J-shape relationship with systolic blood pressure and the primary outcome, although individuals without PAD did not. PAD patients may require a different target blood pressure than those without PAD.

Download full-text


Available from: Yan Gong,
  • Source
    • "Uncontrolled patients did worse. A similar post hoc analysis of INVEST compared participants with and without peripheral arterial disease (PAD) [43]. 41.4% of PAD patients and 26.6% of those without PAD had diabetes (P<0.001). "

    Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications, 08/2011; , ISBN: 978-953-307-597-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Blutdrucksenkung ist einer der wichtigsten Maßnahmen um die vaskulären Komplikationen und die Mortalität bei Patienten mit Diabetes mellitus zu senken. Rezente Studien zeigen, dass die optimalen Blutdruckzielwerte zwischen 130–135 mmHg systolisch und 80 mmHg diastolisch liegen dürften. Niedrigere Blutdruckzielwerte (z. B. 120/80 mmHg) können zwar das Risiko für Schlaganfall und diabetische Nephroopathie weiter senken, sind aber mit einer erhöhten Kardiovaskulären Mortalität assoziiert. Sehr niedrige Blutdruckwerte (< 120 mmHg) sollten insbesondere bei Patienten mit koronarer Herzerkrankung oder mit peripherer arterieller Verschlusskrankheit unbedingt vermieden werden. Der Großteil der Patienten mit Diabetes und Hypertonie benötigt eine antihypertensive Kombinationstherapie, wobei ACE-Inhibitoren oder Angiotensin-II Receptor Blocker in der first-line Therapie eingesetzt werden sollen.
    Wiener klinische Wochenschrift 12/2012; 124(2). DOI:10.1007/s00508-012-0270-6 · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is little evidence from controlled prospective studies to support the low blood pressure goals stipulated for the treatment of hypertension by present guidelines, especially in high-risk patients with diabetes, renal insufficiency or coronary heart disease. Aim of this review is to scrutinize the potential benefit and risk of low blood pressure on the basis of recent studies and secondary analyses of older studies. RESULTS: In patients with coronary heart disease or equivalent or with diabetes lowering systolic blood pressure to 130 to 135 mmHg reduced primary or secondary cardiovascular endpoints in the majority of studies. Between 120 and 129 mmHg some positive effects could be shown in patients with coronary heart disease but not in patients with diabetes or metabolic syndrome. In patients with diabetic or nondiabetic nephropathy including those with proteinurea no convincing data exist which show a better outcome with systolic blood pressure below 130 versus below 140 mmHg. However, several studies suggest that the risk of stroke may decrease by lowering systolic pressure to 120 mmHg or even lower. Below 120 mmHg an increased risk of cardiac and noncardiac events or death was shown in quite a number of studies. In patients between 70 and 80 years, current evidence suggests lowering systolic blood pressure to 135 to 145 mmHg and in those above 80 years to 145 to 155 mmHg. No evidence was found to justify different diastolic pressure goals for different groups of patients; optimal values fall between 70 and 85 mmHg. Limitations of recent studies are short follow-up, few event rates and small differences in achieved pressure between groups leaving uncertainty about long-term effects. PRACTICAL CONSEQUENCES: Apart from prevention of stroke there is sparse evidence that lowering systolic blood pressure below 130 mmHg may be beneficial. Current evidence suggests that lowering systolic and diastolic pressure into a range of 130 to 140/70 to 85 may be adequate for all patients with the exception of children, adolescents and patients over 80 years. Further lowering of systolic pressure seems to offer little additional benefit and lowering diastolic pressure below 70 mmHg might increase risk.
    Wiener klinische Wochenschrift 10/2011; 123(19-20). DOI:10.1007/s00508-011-0022-z · 0.84 Impact Factor
Show more